(A) Prostate malignancy LNCaP (a) or 22RV1 (b) cells were treated with class I HDAC inhibitor MS-275 (1 M) and/or protease inhibitor MG132 at indicated concentration for 48 h
(A) Prostate malignancy LNCaP (a) or 22RV1 (b) cells were treated with class I HDAC inhibitor MS-275 (1 M) and/or protease inhibitor MG132 at indicated concentration for 48 h. cleavage and p-H2A.X in CaP cells with an increase of maspin manifestation but a decrease of AR. Then, treatment with protease inhibitor MG132 did not rescue the above drug-induced loss of AR. In addition, modulation of maspin manifestation by gene recombinant or siRNA technology showed an inverse correlation between manifestation of maspin and AR, as a result influencing the AR-regulated downstream gene transcription (e.g., NKX3.1 and TMPRSS2). Bioinformatics analysis of the data extracted from your National Center for Biotechnology Info Gene Manifestation Omnibus (NCBI GEO) database also exposed an inverse correlation between low maspin manifestation and high AR level in advanced…